Eagle Pharmaceuticals Inc. (NASDAQ:EGRX) Receives $87.61 Consensus Target Price from Brokerages
Shares of Eagle Pharmaceuticals Inc. (NASDAQ:EGRX) have been given a consensus rating of “Buy” by the eight research firms that are presently covering the company. Three investment analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $87.61.
Several equities research analysts have weighed in on the stock. Royal Bank Of Canada restated a “buy” rating and issued a $78.00 price objective on shares of Eagle Pharmaceuticals in a research report on Monday, June 13th. Zacks Investment Research upgraded shares of Eagle Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Monday, July 4th. Mizuho restated a “buy” rating and issued a $66.00 price objective on shares of Eagle Pharmaceuticals in a research report on Friday, June 10th. TheStreet upgraded shares of Eagle Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, August 9th. Finally, RBC Capital Markets restated an “outperform” rating and issued a $80.00 price objective (up previously from $78.00) on shares of Eagle Pharmaceuticals in a research report on Thursday, September 22nd.
In related news, major shareholder Proquest Investments Iv, L.P. sold 24,949 shares of Eagle Pharmaceuticals stock in a transaction that occurred on Monday, August 15th. The shares were sold at an average price of $60.77, for a total transaction of $1,516,150.73. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 18.80% of the company’s stock.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in EGRX. White Pine Capital LLC purchased a new position in Eagle Pharmaceuticals during the second quarter valued at $208,000. LaSalle Street Capital Management LLC bought a new position in shares of Eagle Pharmaceuticals during the second quarter worth $304,000. Columbus Circle Investors bought a new position in shares of Eagle Pharmaceuticals during the second quarter worth $306,000. Rhumbline Advisers raised its position in shares of Eagle Pharmaceuticals by 3.3% in the second quarter. Rhumbline Advisers now owns 9,295 shares of the specialty pharmaceutical company’s stock worth $361,000 after buying an additional 297 shares during the last quarter. Finally, Royal Bank of Canada raised its position in shares of Eagle Pharmaceuticals by 64.3% in the first quarter. Royal Bank of Canada now owns 11,934 shares of the specialty pharmaceutical company’s stock worth $484,000 after buying an additional 4,670 shares during the last quarter. 95.67% of the stock is currently owned by institutional investors and hedge funds.
Shares of Eagle Pharmaceuticals (NASDAQ:EGRX) opened at 63.93 on Wednesday. Eagle Pharmaceuticals has a 12-month low of $33.02 and a 12-month high of $102.48. The firm has a market cap of $999.61 million, a price-to-earnings ratio of 327.85 and a beta of 1.16. The stock’s 50 day moving average is $63.46 and its 200-day moving average is $48.77.
Eagle Pharmaceuticals (NASDAQ:EGRX) last posted its quarterly earnings data on Tuesday, August 9th. The specialty pharmaceutical company reported $0.80 earnings per share for the quarter, beating the consensus estimate of $0.71 by $0.09. The firm earned $40.90 million during the quarter, compared to analysts’ expectations of $43.55 million. Eagle Pharmaceuticals had a net margin of 3.45% and a return on equity of 3.44%. The company’s quarterly revenue was up 581.7% compared to the same quarter last year. During the same quarter last year, the company posted ($0.53) EPS. On average, analysts anticipate that Eagle Pharmaceuticals will post $3.21 EPS for the current fiscal year.
Eagle Pharmaceuticals Company Profile
Eagle Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care and oncology areas. The Company’s product portfolio includes EP-1101 (argatroban); Ryanodex (dantrolene sodium); docetaxel injection, non-alcohol formulation (Non-Alcohol Docetaxel Injection); diclofenac-misoprostol; EP-3101 (Bendamustine Hydrochloride Injection, ready-to-dilute (RTD) concentrate solution), and EP-3102 (rapidly infused bendamustine RTD) (EP-3102 Bendeka).
Receive News & Stock Ratings for Eagle Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.